Top in endocrinology: Illegal dietary supplements, molecular testing for thyroid cancer

The FDA and Federal Trade Commission recently warned against dietary supplements that unlawfully claim to cure, treat or prevent diabetes. It was the top story in endocrinology last week.

Another top story focused on molecular testing for thyroid cancer. New data showed that it was more accurate than other predictors like age and Bethesda category.

Read these and more top stories in endocrinology below:

FDA, FTC issue warnings for dietary supplements claiming to treat diabetes

The FDA and the Federal Trade Commission issued warning letters to 10 companies that market unapproved supplements to treat diabetes and urged consumers not to use the products, which may be harmful. Read more.

Molecular testing most accurately predicts thyroid cancer

Molecular testing was the best predictor for malignancy in indeterminate thyroid nodules when compared with clinical factors, according to findings from a post hoc analysis published in Thyroid. Read more.

Diabetes distress associated with higher HbA1c for young adults, regardless of device use

High diabetes distress is associated with higher HbA1c levels for young adults with type 1 diabetes, including in those using insulin pumps and continuous glucose monitors, according to findings published in Diabetic Medicine. Read more.

Private insurance determines CGM use by young children with type 1 diabetes

Young children newly diagnosed with type 1 diabetes were more likely to use continuous glucose monitoring regularly if they had private insurance, according to findings published in Diabetes Technology & Therapeutics. Read more.

Mortality risk after ischemic stroke increases with time, younger age in diabetes

The risk for mortality after an ischemic stroke increased with longer follow-up time and younger age for adults with diabetes, according to findings published in the Journal of Diabetes and Its Complications. Read more.